Clinical Trial Update: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on trastuzumab deruxtecan (T-DXd) with or without bevacizumab for HER2-low breast cancer with brain metastases; the study is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with Brain Metastases
• Low-expressing Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING